Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2020 Sep 14

PMID 32923904

Citations 16

Authors

Marina Kushnirsky

Lynn G Feun

Sakir H Gultekin

Macarena I de la Fuente

Affiliations

Soon will be listed here.

Citing Articles

Single-cell multi-omics analysis reveals candidate therapeutic drugs and key transcription factor specifically for the mesenchymal subtype of glioblastoma.

Yang Y, Liu Z, Wei Y, He S, Gu A, Li Z Cell Biosci. 2024; 14(1):151.

PMID: 39707474 PMC: 11662595. DOI: 10.1186/s13578-024-01332-3.

The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis.

Lei J, Liu Y, Fan Y Neurosurg Rev. 2024; 47(1):458.

PMID: 39172230 PMC: 11341626. DOI: 10.1007/s10143-024-02664-x.

Glioblastoma Therapy: Past, Present and Future.

Obrador E, Moreno-Murciano P, Oriol-Caballo M, Lopez-Blanch R, Pineda B, Gutierrez-Arroyo J Int J Mol Sci. 2024; 25(5).

PMID: 38473776 PMC: 10931797. DOI: 10.3390/ijms25052529.

BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience.

Trinder S, McKay C, Power P, Topp M, Chan B, Valvi S Front Oncol. 2023; 13:1154246.

PMID: 37124503 PMC: 10140567. DOI: 10.3389/fonc.2023.1154246.

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution.

Di Nunno V, Gatto L, Tosoni A, Bartolini S, Franceschi E Front Oncol. 2023; 12:1067252.

PMID: 36686797 PMC: 9846085. DOI: 10.3389/fonc.2022.1067252.

References

Kim K, Kefford R, Pavlick A, Infante J, Ribas A, Sosman J . Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2012; 31(4):482-9. PMC: 4878037. DOI: 10.1200/JCO.2012.43.5966. View

Peuvrel L, Quereux G, Saint-Jean M, Brocard A, Nguyen J, Khammari A . Profile of vemurafenib-induced severe skin toxicities. J Eur Acad Dermatol Venereol. 2015; 30(2):250-7. DOI: 10.1111/jdv.13443. View

Alexandrescu S, Korshunov A, Lai S, Dabiri S, Patil S, Li R . Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins?. Brain Pathol. 2015; 26(2):215-23. PMC: 8029361. DOI: 10.1111/bpa.12295. View

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart A . BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study. J Clin Oncol. 2018; 36(35):3477-3484. PMC: 6286161. DOI: 10.1200/JCO.2018.78.9990. View

Ascierto P, McArthur G, Dreno B, Atkinson V, Liszkay G, Di Giacomo A . Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016; 17(9):1248-60. DOI: 10.1016/S1470-2045(16)30122-X. View

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C . Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011; 121(3):397-405. DOI: 10.1007/s00401-011-0802-6. View

Dankner M, Rose A, Rajkumar S, Siegel P, Watson I . Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018; 37(24):3183-3199. DOI: 10.1038/s41388-018-0171-x. View

Brown N, Carter T, Kitchen N, Mulholland P . Dabrafenib and trametinib in BRAFV600E mutated glioma. CNS Oncol. 2017; 6(4):291-296. PMC: 6004887. DOI: 10.2217/cns-2017-0006. View

Knobbe C, Reifenberger J, Reifenberger G . Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. 2004; 108(6):467-70. DOI: 10.1007/s00401-004-0929-9. View

10.

Korshunov A, Chavez L, Sharma T, Ryzhova M, Schrimpf D, Stichel D . Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol. 2017; 28(5):656-662. PMC: 7469088. DOI: 10.1111/bpa.12566. View

11.

Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N . RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med. 2018; 25(2):284-291. PMC: 6404779. DOI: 10.1038/s41591-018-0274-5. View

12.

Larkin J, Ascierto P, Dreno B, Atkinson V, Liszkay G, Maio M . Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371(20):1867-76. DOI: 10.1056/NEJMoa1408868. View

13.

Thomas A, Brennan C, DeAngelis L, Omuro A . Emerging therapies for glioblastoma. JAMA Neurol. 2014; 71(11):1437-44. DOI: 10.1001/jamaneurol.2014.1701. View

14.

Baldus S, Schaefer K, Engers R, Hartleb D, Stoecklein N, Gabbert H . Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010; 16(3):790-9. DOI: 10.1158/1078-0432.CCR-09-2446. View

15.

Toll S, Tran H, Cotter J, Judkins A, Tamrazi B, Biegel J . Sustained response of three pediatric BRAF mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget. 2019; 10(4):551-557. PMC: 6355184. DOI: 10.18632/oncotarget.26560. View

16.

Maraka S, Janku F . BRAF alterations in primary brain tumors. Discov Med. 2018; 26(141):51-60. View

17.

Long G, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J . Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; 386(9992):444-51. DOI: 10.1016/S0140-6736(15)60898-4. View

18.

Carlos G, Anforth R, Clements A, Menzies A, Carlino M, Chou S . Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatol. 2015; 151(10):1103-9. DOI: 10.1001/jamadermatol.2015.1745. View

19.

Long G, Flaherty K, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F . Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017; 28(7):1631-1639. PMC: 5834102. DOI: 10.1093/annonc/mdx176. View

20.

Kimura E, Nikiforova M, Zhu Z, Knauf J, Nikiforov Y, Fagin J . High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63(7):1454-7. View